PRESS RELEASE

MolMed: full results of NGR-hTNF trial in mesothelioma published by the leading research journal The Lancet Oncology.

Furthermore, new clinical outcome of NGR-hTNF in brain lymphomas will be presented at the next annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Milan (Italy), May 17th, 2018 – MolMed S.p.A. (MLDM.MI), medical biotechnology company focusing on research, development, manufacturing, and clinical validation of Cell & Gene therapies to treat cancer and rare diseases, today announces that full results of NGR-hTNF Phase III trial in pleural mesothelioma have been recently published by the *The Lancet Oncology*, a leading clinical oncology research journal. Furthermore, new clinical outcome of NGR-hTNF in brain lymphoma will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) that will be held in Chicago from June 1st to June 5th, 2018. Abstracts of the studies, that will both presented at the meeting, have just been made available on ASCO website at the link hhttp://abstracts.asco.org/214/CatView_214_S.html.

The article published by *The Lancet Oncology* highlights NGR-hTNF efficacy in the treatment of mesothelioma, an asbestos-related tumour, with particular reference to patients with a very dismal, refractory or chemo resistant prognosis: though the primary endpoint was not met (i.e. the overall survival improvements for the entire population) the Phase III trial showed indeed a survival improvements and progression-free survival in patients with a more aggressive mesothelioma, thus addressing an unmet medical need, as approved or widely accepted treatments for relapsing patients are not currently available.

Long-term survival outcomes of this Phase III trial, after a more extended follow-up time, will be presented by Dr Vanesa Gregorc, Thoracic Oncology Group Leader at Scientific Institute San Raffaele Hospital in Milan, on Sunday June 3rd, during the session on thoracic malignancies (*Lung Cancer-Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers* ASCO). The summary of main results is available in abstract of the study No 8567.

Furthermore, on Monday June 4th, during the ASCO session on hematological malignancies (*Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia*), a second presentation on NGR-hTNF will be held by Dr Andrés J. M. Ferreri, Head of the clinical research at the Lymphoma Unit of Scientific Institute San Raffaele Hospital in Milan, to illustrate NGR-hTNF activity used in combination with chemotherapy in refractory or resistant to standard treatments patients with brain lymphomas.

Complete and partial responses has been in fact observed as described into abstract No 7575 at the link http://abstracts.asco.org/214/AbstView_214_227227.html.

Riccardo Palmisano, MolMed's CEO, commented: "*The publication of NGR-hTNF results in the treatment of mesothelioma by the most prestigious international oncology journal and the presentation of new outcomes in brain lymphomas at the forthcoming ASCO meeting, confirm the value and the potential of this molecule. Also*

considering these facts, we confirm our strategic goal of finding a partner that could join us to fully exploit both the clinical and industrial development of this important therapeutic option, offering an answer to still unmet medical needs".

NGR-hTNF is a therapeutic agent developed by MolMed targeted to different types of malignancies, which displays anti-tumor activity through its specific binding to blood vessels feeding the cancer and to the concentration of immune system cells into the tumour mass.

For further information on ASCO meeting please see at the link https://iplanner.asco.org/am2018/#/

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development, manufacturing and clinical validation of innovative anticancer therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis® received Orphan Drug Designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy at the end of 2017 and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the company is developing a therapy based on Chimeric Antigen Receptor (CAR), specifically the CAR-T CD44v6, an immune gene therapy project, currently in advanced preclinical development, potentially effective for hematological malignancies and several solid epithelial tumors. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, a GSK gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the framework of innovative anticancer therapies, MolMed's pipeline also includes NGR-hTNF, a therapeutic agent for solid tumors investigated in a broad clinical program, involving more than 1,000 treated patients. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso. OpenZone.

For further information:

Ilaria Candotti
Investor Relations & Communication Manager
MolMed S.p.A.
phone: +39 02 21277.205
fax: +39 02 21277.325
e-mail: investor.relations@molmed.com

Marcella Ruggiero
Press Agent
SEC Relazioni Pubbliche e Istituzionali s.r.l.
phone: +39 02 6249991
cellulare: +39 335 214241
e-mail: ruggiero@secrp.com